



OPEN ACCESS

EDITED AND REVIEWED BY
Klaus Berek,
Innsbruck Medical University, Austria

*CORRESPONDENCE
Heinz Wiendl
✉ heinz.wiendl@uniklinik-freiburg.de

†PRESENT ADDRESS
Heinz Wiendl,
Department of Neurology and
Neurophysiology, Freiburg University,
Freiburg, Germany

RECEIVED 06 February 2025
ACCEPTED 24 February 2025
PUBLISHED 05 March 2025

CITATION
Wiendl H, Barkhof F, Montalban X, Achiron A,
Derfuss T, Chan A, Hodgkinson S, Prat A,
Leocani L, Schmierer K, Sellebjerg F,
Vermersch P, Jin H, Chudecka A, Kloetgen A,
Lin D, Gardner L and De Stefano N (2025)
Corrigendum: Blood biomarker dynamics in
people with relapsing multiple sclerosis
treated with cladribine tablets: results
of the 2-year MAGNIFY-MS study.
Front. Immunol. 16:1571978.
doi: 10.3389/fimmu.2025.1571978

COPYRIGHT
© 2025 Wiendl, Barkhof, Montalban, Achiron,
Derfuss, Chan, Hodgkinson, Prat, Leocani,
Schmierer, Sellebjerg, Vermersch, Jin,
Chudecka, Kloetgen, Lin, Gardner and
De Stefano. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](#). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study

Heinz Wiendl^{1*†}, Frederik Barkhof^{2,3}, Xavier Montalban⁴, Anat Achiron^{5,6}, Tobias Derfuss⁷, Andrew Chan⁸, Suzanne Hodgkinson⁹, Alexandre Prat¹⁰, Letizia Leocani^{11,12,13}, Klaus Schmierer^{14,15}, Finn Sellebjerg^{16,17}, Patrick Vermersch¹⁸, Hulin Jin¹⁹, Anita Chudecka²⁰, Andreas Kloetgen¹⁹, Dongdong Lin²¹, Lidia Gardner²² and Nicola De Stefano²³

¹Department of Neurology, Institute of Translational Neurology, University of Münster, Münster, Germany, ²Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ³Queen Square Institute of Neurology and Centre for Medical Image Computing, University College London, London, United Kingdom, ⁴Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain, ⁵Multiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Israel, ⁶Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁷Department of Neurology, University Hospital Basel, Basel, Switzerland, ⁸Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ⁹Ingham Institute for Applied Medical Research, University of New South Wales Medicine and Liverpool Hospital, Sydney, NSW, Australia, ¹⁰Department of Neurosciences, Université de Montréal, Montréal, QC, Canada, ¹¹Department of Neurology, University Vita-Salute San Raffaele, Milan, Italy, ¹²Experimental Neurophysiology Unit, Scientific Institute IRCCS San Raffaele, Milan, Italy, ¹³Department of Neurorehabilitation Science, Casa di Cura Igea, Milan, Italy, ¹⁴The Blizzard Institute, Centre for Neuroscience, Surgery and Trauma, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ¹⁵Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS, Trust, London, United Kingdom, ¹⁶Danish MS Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark, ¹⁷Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ¹⁸Univ. Lille, Inserm U1172 LiNCog, CHU Lille, FHU Precise, Lille, France, ¹⁹Clinical Measurement Sciences, Merck Healthcare KGaA, Darmstadt, Germany, ²⁰Clinical Research Services, Cytel Inc., Geneva, Switzerland, ²¹Clinical Measurement Sciences, EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, MA, United States, ²²Neurology & Immunology Medical Unit, EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, MA, United States, ²³Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy

KEYWORDS

multiple sclerosis, cladribine tablets, biomarkers, transcriptomics, immunophenotyping, immune reconstitution therapy

A Corrigendum on

Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study

By Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Jin H, Chudecka A, Kloetgen A, Lin D, Gardner L and De Stefano N (2025) *Front. Immunol.* 16:1512189. doi: 10.3389/fimmu.2025.1512189

In the published article, there was an error in Figure 5 as published. In the figure, the legend for the blue and red dots incorrectly read as “|FC| <1.2 & FDR>0.05”. The legend for blue should read “|FC| <1.2 & FDR<0.05” and for red should read “|FC| >1.2 & FDR<0.05”. The corrected Figure 5 and its caption “Gene expression of CD3+ and CD19+ cells at M12, M15 and M24 compared to BL. BL, baseline; FC, fold change; FDR, false discovery rate; M, month.” appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

